Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Alizyme, Prometheus deal

Prometheus received exclusive rights to develop and market AZM's Colal-Pred prednisolone metasulphobenzoate

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE